Nora Therapeutics, Inc.

Nora Therapeutics was a biopharmaceutical company focused on developing treatments for unmet needs in reproductive medicine, specifically addressing in vitro fertilization (IVF) failure and recurrent pregnancy loss. The company was founded in 2007 by Chris McClain and was headquartered in Palo Alto, California.

The company's lead product candidate was NT100, a biologic agent designed to be similar to a naturally occurring protein in the female reproductive tract. The goal of NT100 was to improve the chances of embryo implantation and maintain pregnancy by optimizing maternal-fetal immune tolerance. Nora Therapeutics conducted Phase 2 clinical trials for NT100, including the THRIVE-IVF trial for women with a history of failed IVF cycles and the RESPONSE trial for women with unexplained recurrent pregnancy loss. The company's business model was centered on the research and development of these specialized therapeutics with the aim of bringing an FDA-approved treatment to a market with few options.

Nora Therapeutics was venture-backed, raising a total of $37.8 million over five funding rounds from investors including Novo Holdings, Vivo Capital, Prospect Venture Partners, Rho Ventures, and Burrill & Company. A significant Series B financing round in April 2014 raised $18 million to advance the clinical trials for NT100. Despite its efforts in clinical development and securing funding, Nora Therapeutics ultimately went out of business, with its status listed as closed around January 2017.

Keywords: reproductive medicine, biopharmaceutical, IVF failure, recurrent pregnancy loss, biologic agent, NT100, maternal-fetal immune tolerance, clinical trials, venture capital, therapeutics development, fertility treatment, femtech, drug discovery, embryo implantation, miscarriage prevention, biotechnology, life sciences, pharmaceuticals, Novo Holdings, Vivo Capital